Citi analyst Joanne Wuensch raised the firm’s price target on iRhythm to $183 from $167 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology space following the Q2 reports. Citi views the overall sector as healthy and opened “positive catalyst watches” on Edwards Lifesciences (EW) and Penumbra (PEN). The analyst also added iRhythm (IRTC) to its medtech top picks list, alongside Boston Scientific (BSX) and Edwards.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm initiated with a Buy at BofA on market and margin expansion
- iRhythm initiated with a Buy at BofA
- Dayforce said in talks to be acquired, Soho House to go private: Morning Buzz
- Spruce Point says it’s short iRhythm, sees 40%-70% potential LT downside
- iRhythm announces publication of AVALON study of Zio LTCM